A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoints in chemoprevention trials

Marcel P. Copper, Boudewijn J.M. Braakhuis, Nico de Vries, Guus A.M.S. Van Dongen, Jos J.P. Nauta, Gordon B. Snow

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background. Patients with squamous cell carcinoma of the head and neck have a 10–30% risk of developing a second primary tumor. The concept of “field cancerization” assumes that the whole upper aerodigestive tract is affected and prone to malignant transformation. This study was undertaken to investigate the value of a panel of monoclonal antibodies to identify biomarkers in oral mucosa associated with cancer risk. Such biomarkers may be suitable candidates to serve as intermediate endpoints in cancer chemoprevention trials. Methods. As a model, the expression of antigens was assessed in cytologic preparations obtained from macroscopically normal oral mucosa of patients with tongue carcinoma and of controls. The panel consisted of antibodies against cytokeratin 8, 10, 13, and 19 and the monoclonal antibodies designated K931, K984, E48, Ki‐67, and UM‐A9. Results. Oral mucosa of cancer patients had a more than threefold increased expression of cytokeratin 19 as compared with controls (36.0 versus 11.3%; P < 0.01). Conclusion. Cytokeratin 19 is a potential intermediate endpoint in head and neck cancer chemopreventive trials.

Original languageEnglish
Pages (from-to)825-830
Number of pages6
JournalCancer
Volume71
Issue number3
DOIs
Publication statusPublished - 1 Jan 1993

Cite this

Copper, Marcel P. ; Braakhuis, Boudewijn J.M. ; de Vries, Nico ; Van Dongen, Guus A.M.S. ; Nauta, Jos J.P. ; Snow, Gordon B. / A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoints in chemoprevention trials. In: Cancer. 1993 ; Vol. 71, No. 3. pp. 825-830.
@article{4c796f11eadd46658f70cf72c2bb32a6,
title = "A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoints in chemoprevention trials",
abstract = "Background. Patients with squamous cell carcinoma of the head and neck have a 10–30{\%} risk of developing a second primary tumor. The concept of “field cancerization” assumes that the whole upper aerodigestive tract is affected and prone to malignant transformation. This study was undertaken to investigate the value of a panel of monoclonal antibodies to identify biomarkers in oral mucosa associated with cancer risk. Such biomarkers may be suitable candidates to serve as intermediate endpoints in cancer chemoprevention trials. Methods. As a model, the expression of antigens was assessed in cytologic preparations obtained from macroscopically normal oral mucosa of patients with tongue carcinoma and of controls. The panel consisted of antibodies against cytokeratin 8, 10, 13, and 19 and the monoclonal antibodies designated K931, K984, E48, Ki‐67, and UM‐A9. Results. Oral mucosa of cancer patients had a more than threefold increased expression of cytokeratin 19 as compared with controls (36.0 versus 11.3{\%}; P < 0.01). Conclusion. Cytokeratin 19 is a potential intermediate endpoint in head and neck cancer chemopreventive trials.",
keywords = "biomarkers, chemoprevention, cytokeratins, head and neck cancer, second primary tumors",
author = "Copper, {Marcel P.} and Braakhuis, {Boudewijn J.M.} and {de Vries}, Nico and {Van Dongen}, {Guus A.M.S.} and Nauta, {Jos J.P.} and Snow, {Gordon B.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19930201)71:3<825::AID-CNCR2820710327>3.0.CO;2-X",
language = "English",
volume = "71",
pages = "825--830",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoints in chemoprevention trials. / Copper, Marcel P.; Braakhuis, Boudewijn J.M.; de Vries, Nico; Van Dongen, Guus A.M.S.; Nauta, Jos J.P.; Snow, Gordon B.

In: Cancer, Vol. 71, No. 3, 01.01.1993, p. 825-830.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - A panel of biomarkers of carcinogenesis of the upper aerodigestive tract as potential intermediate endpoints in chemoprevention trials

AU - Copper, Marcel P.

AU - Braakhuis, Boudewijn J.M.

AU - de Vries, Nico

AU - Van Dongen, Guus A.M.S.

AU - Nauta, Jos J.P.

AU - Snow, Gordon B.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Background. Patients with squamous cell carcinoma of the head and neck have a 10–30% risk of developing a second primary tumor. The concept of “field cancerization” assumes that the whole upper aerodigestive tract is affected and prone to malignant transformation. This study was undertaken to investigate the value of a panel of monoclonal antibodies to identify biomarkers in oral mucosa associated with cancer risk. Such biomarkers may be suitable candidates to serve as intermediate endpoints in cancer chemoprevention trials. Methods. As a model, the expression of antigens was assessed in cytologic preparations obtained from macroscopically normal oral mucosa of patients with tongue carcinoma and of controls. The panel consisted of antibodies against cytokeratin 8, 10, 13, and 19 and the monoclonal antibodies designated K931, K984, E48, Ki‐67, and UM‐A9. Results. Oral mucosa of cancer patients had a more than threefold increased expression of cytokeratin 19 as compared with controls (36.0 versus 11.3%; P < 0.01). Conclusion. Cytokeratin 19 is a potential intermediate endpoint in head and neck cancer chemopreventive trials.

AB - Background. Patients with squamous cell carcinoma of the head and neck have a 10–30% risk of developing a second primary tumor. The concept of “field cancerization” assumes that the whole upper aerodigestive tract is affected and prone to malignant transformation. This study was undertaken to investigate the value of a panel of monoclonal antibodies to identify biomarkers in oral mucosa associated with cancer risk. Such biomarkers may be suitable candidates to serve as intermediate endpoints in cancer chemoprevention trials. Methods. As a model, the expression of antigens was assessed in cytologic preparations obtained from macroscopically normal oral mucosa of patients with tongue carcinoma and of controls. The panel consisted of antibodies against cytokeratin 8, 10, 13, and 19 and the monoclonal antibodies designated K931, K984, E48, Ki‐67, and UM‐A9. Results. Oral mucosa of cancer patients had a more than threefold increased expression of cytokeratin 19 as compared with controls (36.0 versus 11.3%; P < 0.01). Conclusion. Cytokeratin 19 is a potential intermediate endpoint in head and neck cancer chemopreventive trials.

KW - biomarkers

KW - chemoprevention

KW - cytokeratins

KW - head and neck cancer

KW - second primary tumors

UR - http://www.scopus.com/inward/record.url?scp=0027417471&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19930201)71:3<825::AID-CNCR2820710327>3.0.CO;2-X

DO - 10.1002/1097-0142(19930201)71:3<825::AID-CNCR2820710327>3.0.CO;2-X

M3 - Article

VL - 71

SP - 825

EP - 830

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -